Since compromised synapses and cognition are improved by safely increasing protein clearance through modulated cathepsin B, Hwang et al.’s research supports the idea that early cathepsin B upregulation is a disease-modifying therapy that may also retard the progression of mild cognitive impairment to dementia [158]. This evidence concerns the gene CTSB and dementia.